Advertisement

Current Oncology Reports

, 20:3 | Cite as

Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery

  • Shahab Ahmed
  • Cathy EngEmail author
Gastrointestinal Cancers (J Meyer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gastrointestinal Cancers

Abstract

Rectal cancer has been successfully managed in the last couple of decades. In the USA, as the initial approach, neoadjuvant concurrent chemoradiation has been associated not only with decrease in tumor size and recurrence but also with higher resection rate with minimal side effects. Data support that addition of chemotherapy to radiotherapy is superior to radiotherapy alone in the neoadjuvant setting. Recent debates have addressed the question of administration of adjuvant chemotherapy following surgery. In this article, we discuss the role of chemotherapy in both the neoadjuvant and the adjuvant settings for locally advanced rectal cancer.

Keywords

Colorectal cancer Rectal cancer Locally advanced rectal cancer Neoadjuvant chemoradiation Adjuvant therapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Shahab Ahmed and Cathy Eng declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Cancer Stat Facts: Colorectal Cancer; National Cancer Institute. 2017. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 16 Jan 2018.
  2. 2.
    ACS. Cancer facts and figures 2016. 2016; Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf.
  3. 3.
    Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109(9):1750–5.  https://doi.org/10.1002/cncr.22625.CrossRefPubMedGoogle Scholar
  4. 4.
    Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci. 2016;12(8):1022–31.  https://doi.org/10.7150/ijbs.15438.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Glimelius B, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi81–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.  https://doi.org/10.1002/bjs.5506.CrossRefPubMedGoogle Scholar
  7. 7.
    Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.  https://doi.org/10.1056/NEJMoa060829.CrossRefPubMedGoogle Scholar
  8. 8.
    Gerard JP, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.  https://doi.org/10.1200/JCO.2006.06.7629.CrossRefPubMedGoogle Scholar
  9. 9.
    Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):5124–30.  https://doi.org/10.1200/JCO.2009.22.0467.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    • Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33. An important study reviewing neoadjuvant versus adjuvant combined chemoradiation for rectal cancer.CrossRefPubMedGoogle Scholar
  11. 11.
    •• Fernandez-Martos, C., et al. Chemoradiation (CRT) followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant CRT and surgery for locally advanced rectal cancer: results of the Spanish GCR-3 randomized phase II trial after a median follow-up of 5 years, in 2014 Gastrointestinal Cancers Symposium. 2014, ASCO: San Fransisco, CA. The study compared different neoadjuvant options for locally advanced rectal cancer. This study may open the door for next step in the management of rectal cancer. Google Scholar
  12. 12.
    Braendengen M, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687–94.  https://doi.org/10.1200/JCO.2007.15.3858.CrossRefPubMedGoogle Scholar
  13. 13.
    Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–90.  https://doi.org/10.1016/S1470-2045(13)70599-0.CrossRefPubMedGoogle Scholar
  14. 14.
    Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger. Ann Oncol. 2015;26(8):1722–8.  https://doi.org/10.1093/annonc/mdv223.CrossRefPubMedGoogle Scholar
  15. 15.
    Calvo FA, Serrano FJ, Diaz-González JA, Gomez-Espi M, Lozano E, Garcia R, et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol. 2006;17(7):1103–10.  https://doi.org/10.1093/annonc/mdl085.CrossRefPubMedGoogle Scholar
  16. 16.
    Marechal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23(6):1525–30.  https://doi.org/10.1093/annonc/mdr473.CrossRefPubMedGoogle Scholar
  17. 17.
    Schou JV, Larsen FO, Rasch L, Linnemann D, Langhoff J, Høgdall E, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol. 2012;23(10):2627–33.  https://doi.org/10.1093/annonc/mds056.CrossRefPubMedGoogle Scholar
  18. 18.
    Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek CBM, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696–701.  https://doi.org/10.1093/annonc/mdu560.CrossRefPubMedGoogle Scholar
  19. 19.
    Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25(7):1356–62.  https://doi.org/10.1093/annonc/mdu147.CrossRefPubMedGoogle Scholar
  20. 20.
    Sainato A, Cernusco Luna Nunzia V, Valentini V, de Paoli A, Maurizi ER, Lupattelli M, et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113(2):223–9.  https://doi.org/10.1016/j.radonc.2014.10.006.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Gastrointestinal Medical OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations